相关实验视频

Updated: Jun 9, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

使用低剂量安洛提尼布和免疫检查点抑制剂的组合疗法用于扩展阶段小细胞肺癌

Han Li¹, Shumin Yuan², Han Wu³

¹Department of Immunotherapy The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou China.

Cancer innovation

|October 29, 2024

概括

低剂量安洛提尼布与免疫检查点抑制剂相结合,对扩散阶段小细胞肺癌 (ES-SCLC) 显示出有前途. 这种组合疗法可以改善无进展生存率 (PFS) 和总生存率 (OS),并具有可管理的副作用.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
免疫治疗是一种免疫疗法.

背景情况:

扩散性小细胞肺癌 (ES-SCLC) 是一个重大的治疗挑战.
对ES-SCLC的二线或后期治疗选择对于改善患者的治疗结果至关重要.

研究的目的:

在ES-SCLC患者中,评估低剂量安洛提尼布与免疫检查点抑制剂 (ICI) 结合的疗效和安全性.
评估这一新型组合疗法的关键生存终点和反应率.

主要方法:

对42名ES-SCLC患者的回顾性分析,这些患者接受了低剂量的anlotinib和ICI (PD-1/PD-L1抑制剂) 治疗.
评估无进展生存率 (PFS),总生存率 (OS),总反应率 (ORR) 和疾病控制率 (DCR).
对与治疗相关的不良事件 (AE) 的评估和预后因素的识别.

主要成果:

观察到PFS的中位数为11.0个月,平均寿命为17.3个月.
总体应答率 (ORR) 为28.5%,疾病控制率 (DCR) 为95.2%.
与治疗相关的不良事件发生在64.3%的患者中,主要是甲状腺功能障碍;3/4级的不良事件很少发生 (4.8%).

结论:

与低剂量的anlotinib和ICI联合治疗在二线或后期ES-SCLC治疗中显示出令人鼓舞的疗效.
这种方案提供了潜在的延长PFS和OS,具有可管理的安全性.
需要进一步的前性研究来证实这些发现.

关键词:

组合免疫疗法组合免疫疗法扩散阶段的小细胞肺癌.免疫检查点抑制剂免疫检查点抑制剂低剂量的抗血管原药物.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...